Patents by Inventor Menashe Elazar

Menashe Elazar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS AND COMPOSITIONS FOR IDENTIFYING ANTI-HCV AGENTS
    Publication number: 20100203498
    Abstract: The invention provides methods and compositions for identifying agents for treating infection by viruses that encode a nucleotide-binding NS4B protein, or functional equivalent thereof, e.g., hepatitis C virus (HCV) or other members of the family Flaviviridae. In general, the methods involve contacting an NS4B nucleotide binding motif (NBM)-containing polypeptide with a candidate agent, and determining the effect of the candidate agent on nucleotide binding activity, a nucleotide hydrolyzing activity, or a nucleotide-dependent RNA binding activity of the polypeptide. A candidate agent that inhibits NS4B polypeptide binding to a nucleotide is an anti-viral agent, e.g., an anti-HCV agent. The invention also features a polynucleotide encoding a NS4B polypeptide having a modified NBM (e.g., which is impaired in NTP binding). The subject methods and compositions find use in a variety of therapeutic and screening applications.
    Type: Application
    Filed: July 27, 2009
    Publication date: August 12, 2010
    Inventors: JEFFREY S. GLENN, SHIRIT EINAV, MENASHE ELAZAR
  • Methods and compositions for identifying anti-HCV agents
    Patent number: 7582428
    Abstract: The invention provides methods and compositions for identifying agents for treating infection by viruses that encode a nucleotide-binding NS4B protein, or functional equivalent thereof, e.g., hepatitis C virus (HCV) or other members of the family Flaviviridae. In general, the methods involve contacting an NS4B nucleotide binding motif (NBM)-containing polypeptide with a candidate agent, and determining the effect of the candidate agent on nucleotide binding activity, a nucleotide hydrolyzing activity, or a nucleotide-dependent RNA binding activity of the polypeptide. A candidate agent that inhibits NS4B polypeptide binding to a nucleotide is an anti-viral agent, e.g., an anti-HCV agent. The invention also features a polynucleotide encoding a NS4B polypeptide having a modified NBM (e.g., which is impaired in NTP binding). The subject methods and compositions find use in a variety of therapeutic and screening applications.
    Type: Grant
    Filed: August 18, 2004
    Date of Patent: September 1, 2009
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Jeffrey S. Glenn, Shirit Einav, Menashe Elazar
  • Methods and compositions for identifying anti-hcv agents
    Publication number: 20060199174
    Abstract: The invention provides methods and compositions for identifying agents for treating infection by viruses that encode a nucleotide-binding NS4B protein, or functional equivalent thereof, e.g., hepatitis C virus (HCV) or other members of the family Flaviviridae. In general, the methods involve contacting an NS4B nucleotide binding motif (NBM)-containing polypeptide with a candidate agent, and determining the effect of the candidate agent on nucleotide binding activity, a nucleotide hydrolyzing activity, or a nucleotide-dependent RNA binding activity of the polypeptide. A candidate agent that inhibits NS4B polypeptide binding to a nucleotide is an anti-viral agent, e.g., an anti-HCV agent. The invention also features a polynucleotide encoding a NS4B polypeptide having a modified NBM (e.g., which is impaired in NTP binding). The subject methods and compositions find use in a variety of therapeutic and screening applications.
    Type: Application
    Filed: August 18, 2004
    Publication date: September 7, 2006
    Inventors: Jeffrey Glenn, Shirit Einav, Menashe Elazar
  • Splice variants of CD40-receptor
    Patent number: 6994994
    Abstract: The present invention concerns six novel variants of alternative splicing of the CD40 receptor.
    Type: Grant
    Filed: July 19, 2000
    Date of Patent: February 7, 2006
    Assignee: Compugent LTD
    Inventors: Kinneret Savitzky, Rami Khosravi, Menashe Elazar
  • Splice variants of CD40-receptor
    Publication number: 20050244877
    Abstract: The present invention concerns six novel variants of alternative splicing of the CD40 receptor.
    Type: Application
    Filed: May 18, 2005
    Publication date: November 3, 2005
    Inventors: Kinneret Savitzky, Rami Khosravi, Menashe Elazar